A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Part of paid clinical trials in Madison, Wisconsin.

Sponsor
Incyte Corporation
Study ID
NCT07018635
Phase
PHASE1
Status
Completed

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • INCB161734 — DRUG
    Oral; Tablet
  • Itraconazole — DRUG
    Oral; Tablet
  • Rifampin — DRUG
    Oral; Tablet
  • Esomeprazole — DRUG
    Oral; Tablet
  • Famotidine — DRUG
    Oral; Tablet

Study Details

This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.

Key Dates

Start date
Jul 16, 2025
Status verified
Nov 2025
Primary completion
Sep 29, 2025
Completion
Sep 29, 2025

Study Design

Enrollment
63 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort 1
    INCB161734 and itraconazole will be administered at protocol defined doses.
  • Experimental: Cohort 2
    INCB161734 and rifampin will be administered at protocol defined doses.
  • Experimental: Cohort 3
    INCB161734 and esomeprazole will be administered at protocol defined doses.
  • Experimental: Cohort 4
    INCB161734 and famotidine will be administered at protocol defined doses.

Primary Outcome Measure

Pharmacokinetics Parameter (PK): Cmax of INCB161734 [ Time Frame: Up to 2 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited MadisonMadisonWisconsin53704-

Find similar trials in Madison, WI

By research site
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison· Madison, WI

Related Studies